CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study (S50.002)

David Weinstein(Coherus BioSciences (United States)), Barbara Finck(Coherus BioSciences (United States)), Lisa Pugliese(Coherus BioSciences (United States)), Hong Tang(Coherus BioSciences (United States)), Alexey Boykо, Robert Zivadinov(Yale University), Dennis Lanfear(Coherus BioSciences (United States))
Cited by 7


Related Papers